Novo Nordisk, the maker of the popular obesity drug Wegovy, announced on Wednesday that it expects slower sales growth in 2025. This projection aligns with market expectations as the feverish demand for Wegovy begins to moderate. The Danish pharmaceutical company forecasts sales growth in local currencies to be between 16% and 24%, a decrease from the 26% growth observed in 2024. Analysts had anticipated a growth rate slightly below 20%.
About the Author
